Kaposi's sarcoma-associated herpesvirus (KSHV) contains a gene encoding a G protein-coupled receptor (KSHV-GPCR) that is homologous to mammalian chemokine receptors. KSHV-GPCR signals constitutively (in an agonist-independent manner) via the phosphoinositide-inositol 1,4,5-trisphosphate pathway. Because it has been proposed that the N terminus (N-TERM) of other GPCRs may act as tethered agonists, we determined whether the N-TERM of KSHV-GPCR is necessary for constitutive signaling activity or ligand binding, or both. We show that replacement of the entire N-TERM of KSHV-GPCR with those of two other GPCRs, deletion of residues within the N-TERM, and disruption of a putative disulfide bond that may hold the N-TERM in close proximity to extracellular loop 3 do not affect constitutive signaling activity but decrease chemokine binding. There were differences in the effects of mutation of the N-TERM on binding of the chemokines growth-related oncogene ␣, which is an agonist, and interferon-␥-inducible protein-10, which is an inverse agonist. The effects on chemokine binding were accompanied by changes in chemokine regulation of KSHV-GPCR signaling. We conclude that the N-TERM is not necessary for constitutive KSHV-GPCR signaling, i.e. the N-TERM is not a tethered agonist, but plays a crucial role in binding of chemokine ligands and of chemokine regulation of KSHV-GPCR signaling.
Kaposi's sarcoma is a multifocal angioproliferative tumor that is often first apparent in the skin or mucous membranes but may involve the viscera as well. Currently, it is the most common AIDS-related tumor. The causative agent for this disease appears to be a member of the herpesvirus family known as Kaposi's sarcoma-associated herpesvirus (KSHV) 1 or human herpesvirus 8, which is also likely involved in the pathogenesis of primary effusion lymphoma and Castleman's disease (1) . One of the genes encoded by KSHV, ORF-74, is a chemokinelike G protein-coupled receptor (KSHV-GPCR). KSHV-GPCR has been found to be a constitutively (or basally) active receptor that signals through the phosphoinositide-inositol 1,4,5-trisphosphate pathway, stimulates cell proliferation, and transforms rodent fibroblasts (2, 3) . KSHV-GPCR binds growth-related oncogene ␣ (Gro␣), interferon-␥-inducible protein-10 (IP-10) and other chemokines (2, 4 -6) . Based on its signaling properties and stimulation of cell proliferation, we suggested that KSHV-GPCR may play an important role in KSHV-induced tumorigenesis (2, 3) . Thus, delineation of the mechanism of regulation of KSHV-GPCR signaling may lead to insights into the pathogenesis of Kaposi's sarcoma and to drugs that may treat Kaposi's sarcoma.
Based on the mechanism of activation of protease-activated receptors (7) in which the N terminus (N-TERM) of the GPCR functions as a "tethered ligand," we considered whether the N-TERM of KSHV-GPCR acts as a tethered agonist to constitutively activate the receptor. Protease-activated receptors are not constitutively active but undergo proteolysis of their extreme N-TERM to uncover the activating domain within the N-TERM. We reasoned that changes within the N-TERM of KSHV-GPCR during viral evolution could have led to its serving as a tethered agonist without requiring protease cleavage. It is noteworthy that mutations within the melanocortin-1 receptor have been suggested to cause constitutive activation by mimicking the effect of agonist (8) and that the binding of the chemokine monocyte chemoattractant protein-1 to the N-TERM of its cognate GPCR, CC chemokine receptor 2 (CCR2), may produce a pseudo-tethered ligand (9) . Because the N-TERMs of other chemokine receptors are involved in ligand binding (10) , we also determined whether the N-TERM was involved in regulation of KSHV-GPCR signaling by chemokines (4 -6) . Out data show that the N-TERM of KSHV-GPCR, although playing an important role in ligand binding and chemokine regulation of signaling, is not necessary for the constitutive activity of the receptor.
EXPERIMENTAL PROCEDURES
Construction of KSHV-GPCR Mutants-All KSHV-GPCR mutants were constructed by PCR using pcDNA 3.1-KSHV-GPCR as template (2) . ⌬(2-11), ⌬(2-11)/4A, ⌬ , and ⌬(2-29) were constructed using the following oligonucleotides: (a) 5Ј-CAAGAATTCCACCATGGATGA-TGATGAATCCTGGAATGAAACT-3Ј, (b) 5Ј-CCGGAATTCTCCGGAC-CACCATGGCTGCTGCTGCATCCTGGAATGAAACTCTAAATATGA-GC-3Ј, (c) 5Ј-CAAGAATTCCACCATGAGCGGATATGACTACTCTGG-AAACTT-3Ј, and (d) 5Ј-CAAGTGGAATTCCACCATGGGAAACTTCAG-CCTAGAAGTGAGCGTGTGT-3Ј, respectively, as sense primers, and (e) 5Ј-ACTGCTTCTTGGGCCAGGAACGCGTAG-3Ј as the antisense primer. EcoRI and EcoRV restriction sites were used to clone the PCR fragments into pcDNA 3.1-KSHV-GPCR.
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C286A used primer g (5Ј-GGTTTAAACGGGCCCTCTAGACTCGAGC-GG-3Ј. The two overlapping primers were as follows: (h) 5Ј-CTAGAA-GTGAGCGTGGCTGAGATGACCACCGTGGTGCCTTACACG-3Ј, and (i) 5Ј-CACGGTGGTCATCTCAGCCACGCTCACTTCTAGGCTGAAGT-TTCCAGA-3Ј for C39A; and (j) 5Ј-ATCCGGGACAGCGCCTATACGCG-GGGGTTGATAAACGTGGGT-3Ј and (k) 5Ј-CCCCCGCGTATAGGCGC-TGTCCCGGATCCAGCGTCGCCTTAG-3Ј for C286A. PCR products for C39A were ligated into pcDNA 3.1-KSHV-GPCR using EcoRI and EcoRV; for C286A, EcoRV and XbaI sites were used. C39A/C286A was constructed through digesting and ligating C39A and C286A.
CXCR3-NT and hCTR3-NT were also generated through overlapping PCR, only that more than one template was involved. For CXCR3-NT, primers l (5Ј-CCGGAATTCTCCGGACCACCATGGTCCTTGAGGTGA-GTGACCACCAAGTG-3Ј) and m (5Ј-GAGTATTCCAACGTTCAGGCT-GAAGTCCTGTGGGCAGGGCGG-3Ј) were used on template pcDNA3-CXCR3, and primers n (5Ј-GACTTCAGCCTGAACGTTGGAA-TACTCTCTCTGATTTTCCTC-3Ј) and e were used on pcDNA 3.1-KSHV-GPCR. Then, the two PCR fragments were combined, and primers l and e were used to amplify them. In the making of hCTR3-NT, primers o (5Ј-CAAGAATTCCACCATGGACTACAAGGACGACGACGA-CAAGATGGATGCGCAGTACAAATGCTAT-3Ј) and p (5Ј-GGTCATCT-CACACATAGTATAGTTGGACCACGTGCGATT-3Ј) were used on template pMT4ProlacFLAGShCTR (11) , and primers q (5Ј-TCCAACT-ATACTATGTGTGAGATGACCACCGTGGTGCCTTAC-3Ј) and e were used on pcDNA 3.1-KSHV-GPCR. Primers o and e were used in the second PCR. The restriction sites EcoRI and EcoRV were used to ligate both PCR products into pcDNA 3.1-KSHV-GPCR.
KSHV-GPCR-(His) 10 -(Gly) 5 -FLAG-Gly-FLAG (wild-type (WT)-H/F) was constructed by PCR using primers r (5Ј-CAAGTGGAATTCCTCG-AGCACCATGGCGGCCGAGGATTTCCTAACCATCTTC-3Ј and s (5Ј-GCCTCTAGAAGATCTCTAACCACCACCACCACCGTGGTGATGAT-GATGATGATGATGATGATGCGTGGTGGCGCCGGACATGAA-3Ј). The PCR fragment of about 1.2 kilobases was isolated using Qiagen spin columns. A second PCR was carried out with primers r and t (5Ј-CGCTCTAGAGTTAACCTACTTGTCGTCGTCGTCCTTGTAGTCG-CCCTTATCATCATCATCCTTGTAATCACCACCACCACCACCGTGG-TG-3Ј) with the isolated PCR fragment as a template. The new PCR fragment was digested with EcoRV and XbaI and ligated into pCDNA3.1-KSHV-GPCR. The H/F mutant plasmids were created by digestion and ligation using EcoRI and EcoRV sites (for ⌬(2-11), ⌬(2-11)/4A, ⌬(1-22), ⌬(2-29), CXCR3-NT, hCTR3-NT, and C39A) or Bsu 36I and EcoRI sites (for C286A and C39A/C286A). All mutants were screened by unique restriction sites and length differentiation and confirmed by sequencing.
Inositol Phosphate Accumulation-COS-1 cells were transfected using the DEAE-dextran method (2) with pcDNA 3.1 plasmids (mock transfectants were cells transfected with plasmid not encoding a receptor) encoding the WT or mutant KSHV-GPCR. Transfected cells were reseeded into 24-well plates 24 h later in Dulbecco's modified Eagle's medium with 5% Nu-Serum (Collaborative Research) and 1 Ci/ml myo- [ 3 H]inositol (NEN Life Science Products). HEK 293EM cells (a generous gift of R. Horlick (Pharmacopeia, Cranbury, NJ)) were transfected using calcium phosphate or SuperFect TM (Qiagen). Forty-eight or 72 h after transfection, the medium was removed, and cells were rinsed with Hanks' balanced salt solution containing 10 mM HEPES, pH 7.4 (HHBSS). The cells were then incubated in HHBSS containing 10 mM LiCl in the absence or presence of various ligands for 2 h at 37°C. Accumulated inositol phosphates were measured using ion-exchange chromatography as described (12) . Inositol phosphate accumulation was analyzed as
Competition Binding-Cells were transfected and seeded as described above except that no myo-[ 3 H]inositol was added. Forty-eight h after reseeding, cells were rinsed once with cold HHBSS and then incubated in cold HHBSS supplemented with 0.5% bovine serum albumin and 10 pM 125 I-Gro␣ (NEN Life Science Products) in the absence or presence of various competing ligands for 4 h at 4°C. At the end of incubation, cells were washed twice with 1 ml of cold HHBSS containing 0.5 M NaCl and lysed with 0.5 ml of 0.4 N NaOH. Cell lysates were transferred to glass test tubes and counted in a gamma counter.
Measurement of Receptor Expression by Enzyme-linked
Immunosorbent Assay-We developed an assay to measure receptor expression using receptors dually tagged with 10 His residues and 2 FLAG epitopes at the C termini (H/F-tagged). COS-1 or HEK 293EM cells were transfected with plasmids encoding H/F-tagged receptors as described above in 10-cm dishes. After 72 h, the cells were scraped in Buffer A (PBS containing 5 g/ml leupeptin and aprotinin and 50 g/ml bacitracin) (2 ml/dish). The scraped cells were pelleted, resuspended in 1.5 ml of Buffer A, and lysed in a Tri-R Star homogenizer. The lysates were centrifuged at 500 ϫ g for 15 min to pellet unbroken cells and nuclei, the supernatants were transferred to a new tube, and Triton X-100 was added to a final concentration of 1%. After 10 min, 100 l of the lysates were transferred into each well of a 96-well plate that had Ni ϩ chelated to polystyrene on the well bottom (Reacti-Bind TM , Pierce). The plate was rinsed once with wash buffer (PBS containing 0.05% Tween 20), and 0.2 ml of 5% milk (in wash buffer) for each well was used for blocking (30 min). After aspiration, anti-FLAG M2 antibody (Sigma) at 1:300 dilution was added for 1 h. The plate was then washed twice with 0.2 ml of wash buffer, and the ␤-galactosidase-conjugated secondary anti-mouse antibody (Tropix) was added for 1 h. After the incubation, the plate was washed as before, 0.07 ml of the ␤-galactosidase substrate (Galacton-Star TM , Tropix) was added for 15 min, and the luminescence was measured in a 96-well plate luminometer (TR 717, Tropix).
RESULTS AND DISCUSSION
We studied WT KSHV-GPCR and the following KSHV-GPCR mutants ( Fig. 1) : CXCR3-NT, in which the first 50 residues of the N-TERM were substituted by the first 50 residues of CXC chemokine receptor 3 (CXCR3), the cognate receptor for IP-10 and monokine-induced by interferon-␥ (13); hCTR3-NT, in which the first 50 residues of the N terminus were substituted by the first 86 residues of human calcitonin receptor type 3 (14) ; ⌬(2-11), lacking amino acid residues 2-11; ⌬(2-11)/4A, lacking residues 2-11 and having Asp-12, Asp-13, Asp-14 and Glu-15 substituted by Ala; ⌬(1-22), lacking residues 1-22; ⌬(2-29), lacking residues 2-29; C39A, in which Cys-39 was substituted by Ala; C286A, in which Cys-286 was substituted by Ala; and C39A/C286A, in which Cys-39 and Cys-286 were substituted by Ala.
All mutant KSHV-GPCRs exhibited constitutive signaling activity when expressed in COS-1 cells (Fig. 2) . Gro␣ is a CXC chemokine that contains the sequence ELR and is a high affinity agonist at KSHV-GPCR (6, 15) . We found that CXCR3-NT, hCTR3-NT, ⌬(2-11)/4A, ⌬ , and ⌬(2-29) did not bind 125 IGro␣ with sufficiently high affinity to be characterized in a binding assay. Indeed, in addition to WT, only ⌬(2-11) exhibited high affinity binding of 125 I-Gro␣. Binding of 125 I-Gro␣ to ⌬(2-11) was only 10% of that to WT. These data show that the N-TERM of KSHV-GPCR is important for binding Gro␣. To estimate the level of expression of receptors that did not bind 125 I-Gro␣ with high affinity, we developed a chemiluminescent enzyme-linked immunosorbent assay using H/F-tagged receptors. The His residues allowed the solubilized receptors to be chelated by Ni ϩ bound to polystyrene at the bottom of wells in a 96-well plate. The FLAG epitopes of the Ni ϩ -adsorbed receptors were bound with the monoclonal antibody M2 and measured with a secondary antibody conjugated to ␤-galactosidase. Fig. 3 illustrates the direct relationship between the luminescent signal and the binding of 125 I-Gro␣ to WT KSHV-GPCR-H/F. These data validate this assay for quantitation of receptor expression. There was no difference in constitutive signaling between untagged and H/F-tagged WT and KSHV-GPCR mutant receptors (data not shown). were 28 and 39% of WT for CXCR3-NT and hCTR3-NT, respectively. The level of expression of CXCR3-NT was 18% of WT, and that of hCTR3-NT was 44% of WT. Thus, the lowered basal levels of signaling of these two KSHV-GPCR mutant receptors appeared to be due to their lower levels of expression (see below). These findings show that the N-TERM of KSHV-GPCR is not needed for basal signaling activity.
To confirm that the N-TERM is not needed for basal signaling and to begin to delineate the domains within the N-TERM that are necessary for binding and regulation of KSHV-GPCR signaling by chemokines, we used KSHV-GPCR mutant receptors that had deletions within their N-TERMs. Fig. 4 illustrates the levels of basal signaling and expression of these mutant receptors in HEK 293EM cells. We consistently observed lower levels of basal signaling and of receptors in cells expressing these mutant receptors than in cells expressing WT KSHV-GPCR. The levels of basal signaling were 20, 64, 33, and 42% of WT, and the levels of expression were 43, 57, 11, and 17% of WT for ⌬(2-11), ⌬(2-11)/4A, ⌬ , and ⌬(2-29), respectively. These N-TERM deletion mutant receptors, therefore, appear to exhibit a lowered basal signaling that is proportional to their lowered levels of expression (see below). These data further support the conclusion that the N-TERM is not involved in constitutive signaling of KSHV-GPCR. Fig. 5 illustrates that the N-TERM of KSHV-GPCR is important for Gro␣ binding. As shown in Fig. 2 , only WT and ⌬(2-11) bound 125 I-Gro␣ with high affinity. The loss of binding in ⌬(2-11)/4A shows that the negatively charged sequence Asp-AspAsp-Glu at positions 12-15 is important for binding Gro␣, which, like other chemokines (16) , contains a number of Lys and Arg residues in its C terminus. The decreased binding of 125 I-Gro␣ to ⌬(2-11) compared with WT is not accounted for by a decrease in the affinity of 125 I-Gro␣ binding (Fig. 5) but represented a lower level of expression of ⌬(2-11) of approximately 40% of WT (Fig. 4) . The binding affinities for Gro␣ were indistinguishable for WT and ⌬(2-11) with equilibrium inhibitory constants (K i values) of 2.8 (2.1-3.7 nM) and 5.3 nM (3.4 -8.3 nM), respectively. By contrast, ⌬(2-11) exhibited a 10-fold decrease in binding affinity for IP-10, which is a CXC chemokine that does not contain the ELR sequence and is an inverse agonist of KSHV-GPCR (4, 6), compared with WT; K i for IP-10 of 120 nM (72-190 nM) for ⌬(2-11) and 12 nM (10 -15 nM) for WT. These data suggested that although both Gro␣ and IP-10 bind to KSHV-GPCR, at least in part, via interacting with the N-TERM, there are different domains within the N-TERM that interact with Gro␣ and IP-10. Fig. 6 illustrates that mutations of the N-TERM that decrease binding of Gro␣ and IP-10 decrease the activities of these chemokines to stimulate and inhibit KSHV-GPCR signaling, respectively. CXCR3-NT, hCTR3-NT, ⌬(2-11)/4A, ⌬(1-22), and ⌬(2-29) did not bind Gro␣, and Gro␣ did not stimulate signaling of these mutant receptors, nor did IP-10 inhibit it. It is not surprising that IP-10 does not inhibit signaling by, for example, hCTR3-NT, because the N-TERM of hCTR3, which is important in binding its cognate ligand calcitonin (17, 18) , is very different from that of KSHV-GPCR. It was perhaps surprising that basal signaling of CXCR3-NT was not inhibited by IP-10, because the N-TERM of CXCR3 is likely involved in binding IP-10 to wild-type CXCR3 (10). We cannot determine whether IP-10 does not bind to CXCR3-NT or whether it binds but does not inhibit signaling because radioiodinated IP-10, which is used to measure binding to CXCR3 (19) , does not exhibit high affinity binding to KSHV-GPCR (data not shown). In contrast to the lack of effects of both Gro␣ and IP-10 on the other mutant receptors, Gro␣ stimulated signaling by ⌬(2-11), but 1000 nM IP-10 did not inhibit it. The lack of inhibition of ⌬(2-11) signaling by IP-10 is not due to its reduced affinity because the concentration of IP-10 used in the experiment is estimated to occupy more than 95% of the available receptors. Therefore, the deletion of residues 2-11 must inhibit some postbinding step that is necessary for IP-10 to inactivate the receptor. That is, there must be a consequence of the binding of IP-10 to residues 2-11 in the N-TERM of KSHV-GPCR, perhaps by mediating a change in IP-10 conformation that allows IP-10 to act as an inverse agonist. Thus, the N-TERM is important in binding chemokines and in allowing a secondary effect that allows chemokines to regulate KSHV-GPCR signaling. We have previously proposed that a conformational change occurs in another ligand, thyrotropin-releasing hormone, upon binding to its cognate GPCR and that the induced conformation is biologically more active than the predominant conformation found in solution (20) .
There is a conserved Cys residue in the N-TERM and another in the third extracellular loop in chemokine receptors that appear to form a disulfide bond and were shown to be important for ligand binding in other chemokine GPCRs (9, 21, 22) . To determine whether Cys residues in the N-TERM and extracellular loop-3 of KSHV-GPCR may form a disulfide bond, we constructed C39A, C286A, and C39A/C286A receptors. All three Cys-to-Ala mutant receptors were expressed at the cell surface and exhibited constitutive signaling activity (Fig. 7) . The levels of basal signaling were 61, 68, and 68% of WT, and the levels of expression were 79, 80, and 29% of WT for C39A, C286A and C39A/C286A, respectively. Thus, as with the other N-TERM mutant KSHV-GPCRs (see above), the lowered basal signaling of the Cys-to-Ala mutant receptors appeared to be due to their lowered levels of expression (see below). We did not observe any high affinity binding of 125 I-Gro␣ to these mutants (data not shown). To support the idea that the decrease in binding was caused by loss of a disulfide bond, we pretreated cells expressing WT receptors with dithiothreitol and N-ethylmaleimide. As expected, we found a marked decrease (Ͼ95%) in high affinity binding of 125 I-Gro␣ to cells in which WT KSHV-GPCR was reduced and alkylated (data not shown). Fig.  8 illustrates that 100 nM Gro␣ stimulated but 1000 nM IP-10 did not inhibit signaling of C39A, C286A, or C39A/C286A receptors. To further delineate the effects of disruption of this disulfide, we measured the concentration dependences of Gro␣ stimulation. Fig. 9 illustrates that there were similar rightward shifts of the Gro␣ concentration-response curves for all three Cys-to-Ala mutant receptors compared with WT. The half-maximally effective concentration (EC 50 ) of Gro␣ was 7.1 nM (4.9 -10 nM) in cells expressing WT and 71-79 nM (19 -340 nM) in those expressing the Cys to Ala substitution mutant receptors. Thus, the lack of high affinity binding appears to be caused by 10-fold decreases in affinities. It is noteworthy that the double mutant, C39A/C286A, did not show a greater increase in EC 50 for Gro␣ than C39A or C286A. This lack of additivity of effects of two mutations has been taken as evidence that the two mutations affect the same aspect of GPCR structure (23) and, therefore, further support the idea that there is a disulfide bond between Cys-39 and Cys-286 in WT KSHV-GPCR. This disulfide bond is important for proper interaction between the N-TERM of KSHV-GPCR and chemokine ligands.
In this study, we probed the role of the N-TERM in KSHV-GPCR signaling. We find that the N-TERM is not required for basal (or constitutive) signaling by KSHV-GPCR. That is, the N-TERM does not serve as a tethered agonist. This is, perhaps, most easily appreciated in Fig. 10 , which shows a direct correlation between the levels of constitutive signaling and of expression for 9 of the 10 KSHV-GPCRs studied herein. We do not understand why ⌬(2-11) appeared to exhibit a lower basal signaling activity relative to its expression than the other receptors. We conclude, therefore, that there is a domain(s) in KSHV-GPCR other than the N-TERM that causes the receptor to signal constitutively. A related conclusion regarding the involvement of a domain in addition to the N-TERM for chemokine activation of a mammalian GPCR has been drawn. contained the N-TERM of one receptor fused to the remainder of the other receptor were able to bind macrophage inflammatory protein 1␣ and eotaxin, the cognate ligands for CCR1 and CCR3, respectively, but neither ligand activated either chimeric receptor. One way of searching for this domain is to see whether there are any differences in amino acid residues in KSHV-GPCR at positions that are highly conserved and are important in signaling in other members of the same GPCR subfamily. This is based on the observations that mutations of critical residues in GPCRs can convert them from basally inactive to constitutively active (25) . There are several residues that are highly conserved in GPCRs of the rhodopsin/␤-adrenergic subfamily, of which KSHV-GPCR is a member, that are involved in signaling but are substituted in KSHV-GPCR. For example, there is a highly conserved (D/E)RY sequence in the intracellular region of transmembrane helix 3 and a highly conserved NPXXY sequence in the intracellular region of transmembrane helix 7 of rhodopsin subfamily members that have been shown to be involved in signaling (26) . Both the D/E of the (D/E)RY sequence and the N of the NPXXY are Val residues in KSHV-GPCR. However, KSHV-GPCR mutants in which either of these residues was substituted by the conserved residue exhibited unchanged basal signaling activities. 2 Mammalian chemokine receptors generally bind chemokines of the CXC or CC family, but not both (27) . For most chemokine receptors, important interactions between ligand and receptor involve the receptor N-TERM (10). KSHV-GPCR binds CXC and CC chemokines (2), and we have now shown that important interactions involve the KSHV-GPCR N-TERM. It is, therefore, interesting that a mammalian seven-transmembrane spanning protein, Duffy antigen/receptor for chemokines, which is a protein with a topology similar to GPCRs but which has not been shown to exhibit signaling activity (28) , binds CXC and CC chemokines with primary interactions involving its N-TERM (29) . There is, however, no sequence homology between the N-TERMs of KSHV-GPCR and Duffy antigen/receptor for chemokines.
We provide evidence for a disulfide bond between Cys-39 in the N-TERM and Cys-286 in extracellular loop-3 of KSHV-GPCR and found that it was important in binding chemokines. A disulfide bond between Cys residues in the same positions of two mammalian chemokine receptors, CCR2 (9) and Duffy antigen/receptor for chemokines (21) , have been described also, and this pair of Cys residues is highly conserved in chemokine receptors in general (16) . A pairs of Cys residues, which appears to form a disulfide bond between the N-TERM and third extracellular loop, is present in the bradykinin B2 receptor, another rhodopsin subfamily member (30) . This pair of Cys residues, however, is not found in most GPCRs.
Our findings that show that the N-TERM of KSHV-GPCR is important for binding and regulation of signaling by chemokine agonists and inverse agonists is similar to the findings with mammalian chemokine GPCRs (10) . These data are consistent with the idea that KSHV-GPCR is a receptor that was "pirated" by KSHV (31) that retains important aspects of mammalian chemokine receptor biology. 
